Ataxia telangiectasia mutated and Rad3-related (ATR) kinase is an important regulator of the DNA damage response, especially in response to replication stress. SKLB-197 is a potent and highly selective ATR inhibitor with an IC50 value of 13 nM. SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
Reference
相关新闻川沙总部
地址: 上海市浦东新区川大路585号
邮编: 201299
电话: +86 (21) 5859-1500（总机）
传真: +86 (21) 5859-6369
海外：
Email: marketing@medicilon.com
Tel: +1 (617) 888-9294(U.S.)
Tel: 0044 7790 816 954 (Europe)
Tel: +82 70-8269-5849 (Korea)
Tel: +81 80-4421-6898 (Japan)
